Therapeutics News and Research

RSS

Y's Therapeutics files for clinical trials in Europe for rheumatoid arthritis and asthma

Y's Therapeutics, a privately held biopharmaceutical company, said today it has submitted applications to the Ethics Committee and Ministry of Health (BfArM) in Germany to begin Phase II clinical trials for its two most advanced projects, YSIL6 for rheumatoid arthritis and YSTH2 for asthma.

26 Jul 2004

New DNA microarray to speed bone disease research

Velcura Therapeutics has announced the development of a custom Affymetrix GeneChip(R) array that aids the development of bone disease therapies by enabling researchers to follow global changes in gene expression during human bone formation.

23 Jul 2004

Cancer Research Technology grants exclusive license to Genentech to patent portfolio of an oncology target

Cancer Research Technology announced today that it has entered into a license agreement granting Genentech, Inc. exclusive worldwide rights to its patent portfolio covering an oncology target discovered in the Molecular Oncology Laboratory (Oxford) of Cancer Research UK.

21 Jul 2004

3M and MicroDose Technologies Inc. team up to bring advanced electronic dry powder inhaler to market

3M and MicroDose Technologies Inc., a privately held drug delivery company based in Monmouth Junction, N.J., announced today that the two companies have entered into an exclusive co-development and joint marketing agreement.

20 Jul 2004

Market research 'World RNAi Markets: Current and Future Outlook'

Gene silencing by RNAi has now been identified as a crucial technology for target validation and therapeutics. By targeting and interfering with messenger RNA (mRNA), RNAi technology blocks the expression of the proteins implicated in disease progression.

19 Jul 2004

Targeted therapeutics capable of preventing or limiting the metastasis of skin cancer

An international team of scientists has identified an important molecular link involved in the spread – or metastasis – of melanoma to other organs such as the lungs.

15 Jul 2004

Strategic analysis of the breast cancer therapeutics pipeline

Strategic partnerships between the pharmaceuticals industry and the biotechnology sector are making breast cancer therapeutics one of the most dynamic segments in the overall oncology market.

15 Jul 2004

Cell Therapeutics receives Fast Track Designation for Pixantrone, treatment for aggressive non-Hodgkin's lymphoma

Cell Therapeutics, Inc. has received fast track designation from the U.S. Food and Drug Administration (FDA) for pixantrone, a novel anthracenedione, being investigated for the potential treatment of relapsed, aggressive non-Hodgkin's lymphoma (NHL).

12 Jul 2004

Myriad Genetics awarded a $14.2 million contract for AIDS and hepatitis research

Myriad Genetics has announced that it has been awarded a five-year, $14.2 million contract by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

10 Jul 2004

Emerging infectious diseases will continue to confront society in unpredictable ways as long as humans and microbes co-exist

Emerging infectious diseases, which have shaped the course of humanity and caused incalculable suffering and death, will continue to confront society in unpredictable ways as long as humans and microbes co-exist

9 Jul 2004

Natural products to be developed as anti-cancer therapeutics

The licence grants Zentaris exclusive worldwide rights for the development, manufacture and marketing of disorazoles, a novel class of natural products with strong anti-cancer potential discovered by GBF researchers.

8 Jul 2004

New leads for the discovery of anthrax antitoxins that could be used in conjunction with antibiotics to treat late-stage anthrax

A team of researchers led by The Burnham Institute’s Robert C. Liddington has determined the crystal structure of the binding complex between anthrax toxin and one of its host receptors.

8 Jul 2004

Children cured of acute lymphocytic leukemia after chemotherapy have a 5-20 times greater risk of developing secondary malignant neoplasm's

The alterations in the children's gene sequence remain embedded within their chromosomes and may pose elevated risk for development of second malignancies and other diseases later in life, cautioned Barry A. Finette, M.D., Ph.D., associate professor of pediatrics at the University of Vermont.

1 Jul 2004

The medical use of marijuana

The medical use of marijuana enjoys wide public support. More than 70% of respondents to recent surveys agree that marijuana should be available medically. Sources: Pew Research Center for the People & the Press conducted by Princeton Survey Research Associates. Feb. 14-19, 2001 and The Gallup Poll. March 19-21, 1999.

30 Jun 2004

Launch of the Jeffrey Modell Diagnostic Center for Primary Immunodeficiencies

Mattel Children's Hospital at UCLA announced the launch of the Jeffrey Modell Diagnostic Center for Primary Immunodeficiencies at UCLA June 28.

29 Jun 2004

Exelixis files new drug application for a proprietary novel anticancer compound

Exelixis, Inc. has submitted an investigational new drug application (IND) to the U.S. Food and Drug Administration (FDA) for XL999, a proprietary novel anticancer compound.

29 Jun 2004

Stimulation or drugs that target the pro-opiomelanocortin system will be effective in treating diabetes or obesity

There’s more than one way to slim a cat - at least that’s the hope of University of Florida obesity researchers, who believe pets and even people may someday benefit from gene therapy research aimed at breaking through the biochemical bottleneck that makes many middle-aged mammals gain weight.

17 Jun 2004

New Cincinnati adult diabetes center

The Diabetes Center at the University of Cincinnati is a joint effort by UC and community leaders to improve diabetes care in the region and open the door to more community programs addressing the health care needs of people with diabetes.

15 Jun 2004

Drug combination reduces cocaine use

Researchers at the Yerkes National Primate Research Center are the first to demonstrate that a combination of drug therapies targeting the region of the brain that controls drug abuse and addiction significantly reduces cocaine use in nonhuman primates.

15 Jun 2004

SARS siRNA studied further to help many respiratory diseases including lung cancer

Intradigm Corporation, has announced achievement of prophylactic and therapeutic effects of siRNA (small interfering RNA) inhibitors of SARS-CoV in non-human primate cells. The results are published in the June 2004 issue of Antiviral Therapy (International Medical Press).

15 Jun 2004

Therapeutics News and Research

Y's Therapeutics files for clinical trials in Europe for rheumatoid arthritis and asthma

New DNA microarray to speed bone disease research

Cancer Research Technology grants exclusive license to Genentech to patent portfolio of an oncology target

3M and MicroDose Technologies Inc. team up to bring advanced electronic dry powder inhaler to market

Market research 'World RNAi Markets: Current and Future Outlook'

Targeted therapeutics capable of preventing or limiting the metastasis of skin cancer

Strategic analysis of the breast cancer therapeutics pipeline

Cell Therapeutics receives Fast Track Designation for Pixantrone, treatment for aggressive non-Hodgkin's lymphoma

Myriad Genetics awarded a $14.2 million contract for AIDS and hepatitis research

Emerging infectious diseases will continue to confront society in unpredictable ways as long as humans and microbes co-exist

Natural products to be developed as anti-cancer therapeutics

New leads for the discovery of anthrax antitoxins that could be used in conjunction with antibiotics to treat late-stage anthrax

Children cured of acute lymphocytic leukemia after chemotherapy have a 5-20 times greater risk of developing secondary malignant neoplasm's

The medical use of marijuana

Launch of the Jeffrey Modell Diagnostic Center for Primary Immunodeficiencies

Exelixis files new drug application for a proprietary novel anticancer compound

Stimulation or drugs that target the pro-opiomelanocortin system will be effective in treating diabetes or obesity

New Cincinnati adult diabetes center

Drug combination reduces cocaine use

SARS siRNA studied further to help many respiratory diseases including lung cancer

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News